# A Study to Compare QLS31905 and Chemotherapy With Placebo and Chemotherapy in Participants With Pancreatic Cancer

Source: https://onco.cc/trials/nct07079228/  
OnCo record `nct07079228` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial testing QLS31905 in pancreatic ductal adenocarcinoma, now recruiting.

## Summary

A Study to Compare QLS31905 and Chemotherapy With Placebo and Chemotherapy in Participants With Pancreatic Cancer is a phase 3 interventional study registered as NCT07079228, led by Qilu Pharmaceutical, and recruiting on the registry. Official title: A Phase 3, Multi-Center, Double-blind, Randomised Study of QLS31905 Plus Chemotherapy Versus Placebo Plus Chemotherapy as First-Line Treatment in Participants With Claudin (CLDN)18.2-Positive Advanced Pancreatic Cancer. Planned enrolment is 602 participants (estimated). The study started in 2025-09-08 and primary completion is expected in 2028-12. No results have been posted on ClinicalTrials.gov.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-11
- Tags: ctgov-ingest
- Registry id: NCT07079228
- Phase: 3
- Setting: A Phase 3, Multi-Center, Double-blind, Randomized Study of QLS31905 Plus Chemotherapy Versus Placebo Plus Chemotherapy as First-Line Treatment in Participants With Claudin (CLDN)18.2-Positive Advanced Pancreatic Cancer
- Sponsor: Qilu Pharmaceutical
- Enrolled: 602

## Sources

- ClinicalTrials.gov NCT07079228: https://clinicaltrials.gov/study/NCT07079228

## Connected records

- cancers: [Metastatic pancreatic ductal adenocarcinoma](https://onco.cc/cancers/metastatic-pdac/), [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/)
- drugs: [QLS31905](https://onco.cc/drugs/qls31905/)
- companies: [Qilu Pharmaceutical](https://onco.cc/companies/qilu-pharmaceutical/)

---
JSON: https://onco.cc/api/v1/entities/nct07079228.json